![](https://ml.globenewswire.com/media/d7849c0a-e9d0-4f9d-8d85-95787f5736bf/small/captura-de-pantalla-2023-11-10-082355-big-png.png)
Lipella Pharmaceuticals Initiates Phase 2a Trial for LP-310 in Oral Lichen Planus, Enrolls First Patients
PITTSBURGH, July 29, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced the enrollment of the …